Cell type-specific integrated stress response modulation for neuroinflammatory disease therapeutics

Overview

This research program investigates the cell type-specific role of the integrated stress response (ISR), a conserved signaling pathway implicated in neuroinflammatory and neurodegenerative diseases such as multiple sclerosis, Alzheimer's disease, and Amyotrophic Lateral Sclerosis. Prior clinical efforts to manipulate ISR broadly have failed, likely because ISR activity varies across cell types—activating it in some cells may worsen disease while protecting others. This program aims to elucidate cell type-specific ISR mechanisms to enable targeted therapeutic strategies that modulate downstream pathways in defined cell populations.

Proof-of-concept findings in Alzheimer's disease and multiple sclerosis models demonstrate that microglia, the brain's primary immune cells, show significantly elevated ISR in both diseases, while oligodendrocyte lineage cells do not. Using novel cell type-specific ISR mouse models, the team has shown that microglial ISR exacerbates amyloid and tau pathology and synapse loss in Alzheimer's models, whereas blocking microglial ISR is ameliorative. These results provide direct in vivo evidence that ISR renders microglia neurodegenerative and identify cell type-specific ISR pathways as promising therapeutic targets.

Technical specifications

Key features and methodology:

• Two complementary cell type-specific ISR mouse models: a chemogenetic model to selectively activate ISR and a phosphomutant model to prevent ISR activation
• Validated in established disease models including 5xFAD amyloidosis mice, PS19 tauopathy mice, and cuprizone-induced demyelination for multiple sclerosis
• Multi-modal validation using immunofluorescence, ELISA, qPCR, and Western blot to confirm cell type-specific ISR activity
• Planned crosses with microglial Cre lines (Cx3cr1, Tmem119) and oligodendrocyte lineage Cre lines (Plp, Pdgfra) for cell type-specific interrogation
• Cell type-specific ribosomal profiling to characterize molecular signatures of ISR-modified microglia and oligodendrocytes
• Clinical scoring and immunofluorescence to assess demyelination and neurodegeneration outcomes

Collaborative framework:

The program is structured for a two-year validation effort, with Year 1 focused on characterizing how microglial or oligodendrocytic ISR impacts cuprizone-induced demyelination, and Year 2 dedicated to molecular signature analysis. The program includes collaboration with an adjacent laboratory for specialized expertise.

Technology readiness level

The program is currently at Technology Readiness Level 3–4 (TRL 3–4), representing proof-of-concept validation in relevant animal models. The core hypothesis has been validated in Alzheimer's disease models, with demonstrated causal evidence that microglial ISR drives neurodegeneration. Future validation work will extend these findings to multiple sclerosis models using the cuprizone demyelination paradigm. The research is positioned to transition toward therapeutic development through industry collaboration, with the goal of identifying druggable downstream pathways specific to ISR-activated microglia and oligodendrocytes. The program is actively seeking industry partners to provide therapeutic compounds targeting identified pathways and funding for reagents and key personnel.